Fred Hutchinson Cancer Research Center | Seattle, WA
Status and phase
Conditions
Treatments
About
This Phase 1/2 clinical study will evaluate evorpacept (ALX148) in combination with azacitidine for the treatment of patients with higher risk myelodysplastic syndrome (MDS).
Full description
The Phase 1 will consist of a dose escalation of evorpacept (ALX148) in combination with azacitidine to evaluate safety and tolerability, and to identify the recommended Phase 2 dose of ALX148 in combination with azacitidine. The Phase 2 will evaluate the efficacy of evorpacept (ALX148) in combination with azacitidine compared to azacitidine alone for patients with previously untreated higher risk MDS.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
65 participants in 2 patient groups
Loading...
Central trial contact
Abraham Fong, MD, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal